EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Device-Therapy in Chronic Heart Failure: Cardiac Contractility Modulation Versus Cardiac Resynchronization Therapy

Goekhan Yuecel iD, Leo Gaasch, Abbass Kodeih, Svetlana Hetjens, Babak Yazdani, Stefan Pfleger, Daniel Duerschmied, William T Abraham, Ibrahim Akin, Juergen Kuschyk

ESC Heart Failure · 2025

DOI: 10.1002/ehf2.15067 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Goekhan Yuecel und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidel…. Hauptthemen laut MEDLINE: Heart Failure, Cardiac Resynchronization Therapy, Myocardial Contraction, Stroke Volume. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: DZHK, Deutsche Forschungsgemeinschaft, Deutsches Zentrum für Herz-Kreislaufforschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Cardiac implantable electrical devices such as cardiac resynchronization therapy with defibrillator (CRT-Ds) or cardiac contractility modulation (CCMs) are therapy options for patients with symptomatic heart failure (HF) and reduced left ventricular ejection fraction (LVEF) despite optimal medical treatment. As yet, a comparison between both devices has not been performed. Methods and results The Mannheim Cardiac Resynchronization Therapy Registry (MARACANA) and the Mannheim Cardiac Contractility Modulation Observational Study (MAINTAINED) included all patients who received CRTs or CCMs in our medical centre between 2012 and 2021. For the present analysis, we retrospectively compared patients provided with either CRT-Ds (n = 220) or CCMs with additional defibrillators (n = 105) regarding New York Heart Association classification (NYHA), LVEF, tricuspid annular plane systolic excursion (TAPSE), QRS-width and other HF modification aspects after 12 months. Before implantation, CCM patients presented with lower LVEF (23.6 ± 6.2 vs. 26.3 ± 6.5%) and worse NYHA (3.03 ± 0.47 vs. 2.81 ± 0.48, both P < 0.05), compared with CRT-D patients. Follow-up improvements in NYHA (2.43 ± 0.67 vs. 2.28 ± 0.72), LVEF (30.5 ± 10.7 vs. 35.2 ± 10.5%) and TAPSE (17.2 ± 5.2 vs. 17.1 ± 4.8 to 18.9 ± 3.4 vs. 17.3 ± 3.6 mm, each P < 0.05) were comparable. The intrinsic QRS-width was stable with CCM (109.1 ± 18 vs. 111.7 ± 19.7 ms, P > 0.05), while the paced QRS-width with CRT-D after 12 months was lower than intrinsic values at baseline (157.5 ± 16.5 vs. 139.2 ± 16 ms, P < 0.05). HF hospitalizations occurred more often for CCM than CRT-D patients (45.7 vs. 16.8%/patient years, odds ratio 4.2, P < 0.001).

Conclusions

Chronic heart failure patients could experience comparable 12-month improvements in functional status and ventricular reverse remodelling, with appropriately implanted CCMs and CRT-Ds. Differences in HF hospitalization rates may be due to the more advanced HF of CCM patients at implantation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureCardiac Resynchronization TherapyMyocardial ContractionStroke VolumeVentricular Function, LeftRegistriesDefibrillators, ImplantableCardiac Resynchronization Therapy DevicesHumansMaleFemaleRetrospective StudiesAgedMiddle AgedFollow-Up StudiesChronic DiseaseTreatment Outcome

Stichwörter der Autor:innen

CCMCIEDCRTChronic heart failure

Autor:innen und Institutionen

  • Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • European Center for AngioScience (ECAS) and German Center for Cardiovascular Research (DZHK) Partner Site Heidelberg/Mannheim, Mannheim, Germany.
  • Department of Medical Statistics and Biomathematics, Medical Faculty Mannheim, University Medical Centre Mannheim, Heidelberg University, Mannheim, Germany.
  • Fifth Department of Medicine, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio, USA.

ORCID-Profile: Goekhan Yuecel

Förderung

  • DZHK
  • Deutsche Forschungsgemeinschaft
  • Deutsches Zentrum für Herz-Kreislaufforschung

Zitieren

APA

Yuecel, G., Gaasch, L., Kodeih, A., Hetjens, S., Yazdani, B., Pfleger, S., Duerschmied, D., Abraham, W. T., Akin, I., & Kuschyk, J. (2025). Device-Therapy in Chronic Heart Failure: Cardiac Contractility Modulation Versus Cardiac Resynchronization Therapy. ESC Heart Failure. https://doi.org/10.1002/ehf2.15067

Vancouver

Yuecel G, Gaasch L, Kodeih A, Hetjens S, Yazdani B, Pfleger S, et al. Device-Therapy in Chronic Heart Failure: Cardiac Contractility Modulation Versus Cardiac Resynchronization Therapy. ESC Heart Failure. 2025. doi:10.1002/ehf2.15067

BibTeX
@article{Yuecel2025,
  author = {Yuecel, Goekhan and Gaasch, Leo and Kodeih, Abbass and Hetjens, Svetlana and Yazdani, Babak and Pfleger, Stefan and Duerschmied, Daniel and Abraham, William T and Akin, Ibrahim and Kuschyk, Juergen},
  title = {Device-Therapy in Chronic Heart Failure: Cardiac Contractility Modulation Versus Cardiac Resynchronization Therapy},
  journal = {ESC Heart Failure},
  year = {2025},
  doi = {10.1002/ehf2.15067}
}
Kostenlos starten →